Targeting IL-4 for the Treatment of Atopic Dermatitis

Atopic dermatitis (AD) is an immune-mediated inflammatory skin disease characterized by a predominant type 2 immune response. Type 2 immunity is driven by multiple cytokines, including interleukin (IL)‑4 and IL-13 that are considered central to AD pathogenesis and key therapeutic targets. The dual i...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiricozzi, Andrea, Maurelli, Martina, Peris, Ketty, Girolomoni, Giampiero
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532907/
https://www.ncbi.nlm.nih.gov/pubmed/33062619
http://dx.doi.org/10.2147/ITT.S260370
_version_ 1783590023713521664
author Chiricozzi, Andrea
Maurelli, Martina
Peris, Ketty
Girolomoni, Giampiero
author_facet Chiricozzi, Andrea
Maurelli, Martina
Peris, Ketty
Girolomoni, Giampiero
author_sort Chiricozzi, Andrea
collection PubMed
description Atopic dermatitis (AD) is an immune-mediated inflammatory skin disease characterized by a predominant type 2 immune response. Type 2 immunity is driven by multiple cytokines, including interleukin (IL)‑4 and IL-13 that are considered central to AD pathogenesis and key therapeutic targets. The dual inhibition of these two cytokines or the selective inhibition of IL-13 proved elevated efficacy in treating AD, whereas the selective inhibition of IL-4 has been poorly investigated as IL-4 inhibiting agents did not show any advance in clinical development programs. This review describes the pathogenic role of IL-4 in AD and briefly resumes the main features of compounds selectively blocking IL-4.
format Online
Article
Text
id pubmed-7532907
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-75329072020-10-14 Targeting IL-4 for the Treatment of Atopic Dermatitis Chiricozzi, Andrea Maurelli, Martina Peris, Ketty Girolomoni, Giampiero Immunotargets Ther Review Atopic dermatitis (AD) is an immune-mediated inflammatory skin disease characterized by a predominant type 2 immune response. Type 2 immunity is driven by multiple cytokines, including interleukin (IL)‑4 and IL-13 that are considered central to AD pathogenesis and key therapeutic targets. The dual inhibition of these two cytokines or the selective inhibition of IL-13 proved elevated efficacy in treating AD, whereas the selective inhibition of IL-4 has been poorly investigated as IL-4 inhibiting agents did not show any advance in clinical development programs. This review describes the pathogenic role of IL-4 in AD and briefly resumes the main features of compounds selectively blocking IL-4. Dove 2020-09-29 /pmc/articles/PMC7532907/ /pubmed/33062619 http://dx.doi.org/10.2147/ITT.S260370 Text en © 2020 Chiricozzi et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Chiricozzi, Andrea
Maurelli, Martina
Peris, Ketty
Girolomoni, Giampiero
Targeting IL-4 for the Treatment of Atopic Dermatitis
title Targeting IL-4 for the Treatment of Atopic Dermatitis
title_full Targeting IL-4 for the Treatment of Atopic Dermatitis
title_fullStr Targeting IL-4 for the Treatment of Atopic Dermatitis
title_full_unstemmed Targeting IL-4 for the Treatment of Atopic Dermatitis
title_short Targeting IL-4 for the Treatment of Atopic Dermatitis
title_sort targeting il-4 for the treatment of atopic dermatitis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532907/
https://www.ncbi.nlm.nih.gov/pubmed/33062619
http://dx.doi.org/10.2147/ITT.S260370
work_keys_str_mv AT chiricozziandrea targetingil4forthetreatmentofatopicdermatitis
AT maurellimartina targetingil4forthetreatmentofatopicdermatitis
AT perisketty targetingil4forthetreatmentofatopicdermatitis
AT girolomonigiampiero targetingil4forthetreatmentofatopicdermatitis

Ejemplares similares